|Bid||242.00 x 0|
|Ask||0.00 x 0|
|Day's Range||240.60 - 247.60|
|52 Week Range||169.10 - 308.50|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||25.05|
|Earnings Date||Aug 13, 2020|
|Forward Dividend & Yield||4.10 (1.67%)|
|Ex-Dividend Date||Mar 25, 2020|
|1y Target Est||302.29|
H. Lundbeck (HLUYY) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Danish drugmaker Lundbeck <LUN.CO> beat first-quarter sales expectations on Tuesday and stuck to its annual forecast, helped by strong sales of drugs as patients requested longer prescriptions and stockpiled drugs due to the coronavirus pandemic. "Demand has been strong, but we also recognize that we have benefited from patients gaining longer refill prescriptions as well as some stocking of products in many countries in response to the COVID-19 pandemic," Chief Executive Deborah Dunsire said in a statement. Lundbeck, which specialises in treatments for mental disorders, joins a string of pharmaceutical companies either maintaining or raising their yearly sales outlook as lockdowns to curb the spread of the coronavirus has led patients and pharmacies to stockpile drugs.
Danish drugmaker Lundbeck beat first-quarter sales expectations on Tuesday, helped by strong sales from key drugs which benefitted from stock-piling and longer-lasting prescriptions due to the coronavirus pandemic, it said in a statement. The Copenhagen-based company posted quarterly sales of 4.56 billion Danish crowns ($661.25 million), above an average of 4.34 billion forecast by analysts in a Refinitiv Eikon poll, and an 8% increase from the same period last year. Lundbeck, which specializes in treatments for mental disorders, said it would keep its annual financial guidance of sales in the range of 17.4 to 18.0 billion crowns.
It hasn't been the best quarter for H. Lundbeck A/S (CPH:LUN) shareholders, since the share price has fallen 17% in...
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see H. Lundbeck...
To the annoyance of some shareholders, H. Lundbeck (CPH:LUN) shares are down a considerable 35% in the last month...
Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Anders Götzsche to its Board of Directors. Mr. Götzsche will serve as the Chair of Obsidian's Audit Committee. Mr. Götzsche currently serves as the Executive Vice President and Chief Financial Officer of H. Lundbeck A/S (LUN.CO).
As you might know, H. Lundbeck A/S (CPH:LUN) recently reported its yearly numbers. The result was positive overall...
Zogenix stock plummeted Friday after the biotech company's successful Phase 3 study of an experimental seizure medicine, known as Fintepla, still lagged more bullish expectations.
Danish drugmaker Lundbeck posted fourth quarter sales slightly above expectations on Thursday, helped by a stronger performance from key drugs, and said it expected to return to sales growth in 2020. Lundbeck, which specialises in treatments for illnesses such as Alzheimer's and depression, posted fourth quarter sales of 4.42 billion Danish crowns ($650.54 million), above an average of 4.26 billion forecasted by analysts in a Refinitiv poll.
Could H. Lundbeck A/S (CPH:LUN) be an attractive dividend share to own for the long haul? Investors are often drawn to...
Danish drugmaker Lundbeck raised its outlook for full-year sales and profit on Tuesday following better-than-expected third quarter sales of key drugs and said it expected to return to growth next year, driving its shares over 5% up. Lundbeck, which specialises in treatments for illnesses such as Alzheimer's and depression, has struggled with patent expirations on existing drugs, which has dampened sales this year. Lundbeck's sales dropped 9.4% in the first nine months due to expected tough competition from generic products on epilepsy drug Onfi, previously its biggest brand, whose patent expired in October last year.
H. Lundbeck A/S (CPH:LUN) shareholders might be concerned after seeing the share price drop 13% in the last quarter...
Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 84% by the stock market's close on Monday.
Danish pharmaceutical company H. Lundbeck A/S will acquire Alder Biopharmaceuticals for nearly $2 billion in a deal that sent Alder stock rocketing 83% in early trading Monday.
Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares.
Alder Biopharmaceuticals surges after rival Danish drugmaker Lundbeck announces plans to acquire the company and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.
Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday. The deal, expected to close in the fourth quarter of this year, will be funded through existing cash resources and bank financing, Lundbeck said. Lundbeck will buy outstanding shares of Alders in an upfront payment of $18 per share.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll look at H...
In this article we are going to estimate the intrinsic value of H. Lundbeck A/S (CPH:LUN) by taking the expected...
Since H. Lundbeck A/S (CPH:LUN) released its earnings in March 2019, analyst forecasts appear to be pessimistic, with...